MapLight director proposes $116K stock sale

The notice places the proposed sale alongside 46,377,832 common shares outstanding.

Rhea-AI Filing Summary

MapLight Therapeutics, Inc. (MPLT) director Robert Malenka reported a proposed sale of 14,809 common shares, with an approximate sale date of October 15, 2026. The reported aggregate market value is $115,658.29. The securities are identified as restricted stock units acquired from the issuer on October 1, 2026; Morgan Stanley Smith Barney LLC is listed in the broker information.

Key Figures

Common shares proposed for sale: 14,809 shares Aggregate market value: $115,658.29 Common shares outstanding: 46,377,832 shares

3 metrics

Common shares proposed for sale 14,809 shares Approximate sale date: October 15, 2026

Aggregate market value $115,658.29 Reported for the proposed sale

Common shares outstanding 46,377,832 shares Count listed in the securities information

Key Terms

Restricted Stock Units, Rule 144

2 terms

Restricted Stock Units financial

"Restricted Stock Units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Rule 144 regulatory

"paragraph (a) of Rule 144"

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many MPLT shares does Robert Malenka propose to sell?

Robert Malenka, a director, reported a proposed sale of 14,809 common shares, with an approximate sale date of October 15, 2026, and a reported aggregate market value of $115,658.29.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/15/2026 - 04:37 PM EDT Accepted by SEC EDGAR 10/15/2026 - 04:37 PM EDT Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0002021198
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	MapLight Therapeutics, Inc.
SEC File Number	001-42914
Address of Issuer	800 Chesapeake Drive Redwood City CALIFORNIA 94063
Phone	6179846300
Name of Person for Whose Account the Securities are To Be Sold	ROBERT MALENKA
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Director

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	14809	115658.29	46377832	10/15/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	10/01/2026	Restricted Stock Units	Issuer			14809	10/01/2026	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks
Date of Notice	10/15/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	12/26/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Robert Malenka
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)